Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cilengitide + procarbazine + temozolomide
- Development stage
- Discontinued
- Lead developer
- EMD Serono
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of cilengitide (a selective αvβ3 and αvβ5 integrin inhibitor), procarbazine (an alkylating agent), and temozolomide (an oral alkylating agent). This regimen was specifically investigated for newly diagnosed glioblastoma multiforme with unmethylated MGMT promoter status, which typically has a poor prognosis with standard treatments. The combination aims to overcome temozolomide resistance through metronomic dosing and multi-targeted approach.
02
Targets
αVβ5 (Integrin αVβ5)αVβ3 (Integrin αVβ3)DNAAGT (O6-methylguanine-DNA methyltransferase)
Beyond the preview
Go deeper on cilengitide + procarbazine + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cilengitide + procarbazine + temozolomide.